Technology Transfer

IGB strives to transfer the technology developed in its laboratories into commercial applications and operates as an incubator. IGB fostered the faculty founding of several startup companies. The success rate of these startup companies is well above the national average. These include:

  • Antigen Discovery Inc. (Irvine, CA) [faculty founder: P. Felgner].
    Antigen discovery is a proteome- on-a chip company for antigen discovery and other immunological applications. IGB faculty were instrumental in helping the company develop its protein chip technology as well as the computational technologies required for analyzing the complex signals produced by these chips.
  • Verdezyne, Inc. (Carslbad, CA) [faculty founders: GW Hatfield, R Lathrop].
    Verdezyne was an industrial biotechnology company based on technologies developed at UCI to produce industrial chemicals from renewable non-food sources. Verdezyne employed more than 100 employees including several UCI graduates. It was liquidated in 2018.
  • Reaction Explorer, LLC (Irvine, CA) [faculty founders: P. Baldi and former MD/PhD Student J Chen].
    Reaction Explorer has developed an expert system for organic reactions in chemistry which is used to power an interactive education system for college-level organic chemistry. Wiley has acquired an exclusive license to the system and is distributing it worldwide.
  • Actavalon Inc. (Corona del Mar, CA) [faculty founders: R Amaro, G. W. Hatfield, P Kaiser, R. Lathrop, S. Rychnovsky].
    Actavalon is a pharmaceutical company employing proprietary computational, biological, and chemical methods to develop small molecule drugs for treatment of a broad spectrum of human cancers. http:/
  • 4Design Biosciences LLC (Corona del Mar) [faculty founders: S George, G.W. Hatfield, C.C. Hughes, A. Lee].
    4D scientists have pioneered the development of high-throughput microfluidic devices for multiple physiologically-relevant 3D human micro-organ systems that receive their oxygen, nutrients, and drugs through living blood vessels, just as tissues do in the body.
  • Group IV Biosystems Inc. (Newport Beach, CA) [faculty founders: P Baldi, R. Lathrop, E. Mjolsness, S. Sandmeyer, G.W. Hatfield].
    The company was created with the vision of combining strengths in pathway and metabolic modeling, gene synthesis, and protein structure prediction and modeling to address problems in synthetic biology and green chemistry. The market proved to be insufficient to support this activity. The company was closed.
  • Spraldi Technologies LLC [faculty founders: G. W. Hatfield, UCI; Jason Chen, UCR].
    The Spraldi technology combined the applications of surface plasmon resonance and mass spectrometry in a high throughput system to simultaneously obtain protein identification and ligand binding data. However, this technology proved to be incompatible with newly designed mass spectrometry instruments and the company was closed.
  • Aracari Biosciences, Inc. (Irvine, CA) [faculty founders: G.W. Hatfield, C Hughes, S George, A Lee]
    (formerly: Kino Biosciences, Inc.) The company utilizes patented vascularized micro-tissues, and experience and knowledge of the drug discovery pipeline to accelerate drug discovery.
  • DocBot (Irvine, CA) [faculty founder: W. Karnes]
    The company utilizes AI technology originally developed in the Baldi laboratory to automatically identify polyps in colonoscopy videos with the mission to reduce colon cancer rates to zero.